Capital World Investors’s Neurocrine Biosciences NBIX Stock Holding History

Capital World Investors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-300,000	Closed	-$36.9M	–	553
2018 Q3	$36.9M	Sell	300,000 -358,000	-54%	-$40.6M	0.01%	405
2018 Q2	$64.6M	Sell	658,000 -30,000	-4%	-$2.69M	0.01%	341
2018 Q1	$57.1M	Hold	688,000	–	–	0.01%	352
2017 Q4	$53.4M	Hold	688,000	–	–	0.01%	348
2017 Q3	$42.2M	Hold	688,000	–	–	0.01%	369
2017 Q2	$31.6M	Sell	688,000 -175,000	-20%	-$8.49M	0.01%	379
2017 Q1	$37.4M	Sell	863,000 -325,000	-27%	-$13.9M	0.01%	373
2016 Q4	$46M	Sell	1,188,000 -293,000	-20%	-$13.3M	0.01%	351
2016 Q3	$75M	Hold	1,481,000	–	–	0.02%	302
2016 Q2	$67.3M	Hold	1,481,000	–	–	0.02%	309
2016 Q1	$58.6M	Buy	1,481,000 +238,500	+19%	+$9.46M	0.02%	320
2015 Q4	$70.3M	Hold	1,242,500	–	–	0.02%	311
2015 Q3	$49.4M	Sell	1,242,500 -170,200	-12%	-$8.23M	0.01%	346
2015 Q2	$67.5M	Sell	1,412,700 -52,500	-4%	-$2.23M	0.02%	332
2015 Q1	$58.2M	Buy	1,465,200 +315,000	+27%	+$11.3M	0.02%	350
2014 Q4	$25.7M	Hold	1,150,200	–	–	0.01%	426
2014 Q3	$18M	Hold	1,150,200	–	–	0.01%	440
2014 Q2	$17.1M	Hold	1,150,200	–	–	﹤0.01%	433
2014 Q1	$18.5M	Buy	1,150,200 +625,200	+119%	+$10.7M	0.01%	427
2013 Q4	$4.9M	Hold	525,000	–	–	﹤0.01%	471
2013 Q3	$5.94M	Buy	+525,000	New	+$7.22M	﹤0.01%	468

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors's NBIX Position: Q4 2018 in Review

Capital World Investors sold out of Neurocrine Biosciences (NBIX) in Q4 2018, closing a stake of 300,000 shares — an estimated $36.9M sold.

Capital World Investors first reported a position in NBIX in Q3 2013 and held it in 21 quarters. The position peaked at $75M in Q3 2016. 331 funds tracked by Wall St. Rank hold NBIX as of Q4 2018.

Capital World Investors reported no remaining Neurocrine Biosciences position as of Q4 2018 after selling out during the quarter.
Capital World Investors sold 300,000 Neurocrine Biosciences shares in Q4 2018, an estimated $36.9M.
Capital World Investors first reported a position in Neurocrine Biosciences in Q3 2013 and held it in 21 quarters.
Capital World Investors's Neurocrine Biosciences position peaked at $75M in Q3 2016.
331 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2018.

Based on Capital World Investors's 13F filing for Q4 2018, filed 14 Feb 2019.